Efforts to find new uses for old drugs in COVID-19 patients are gathering pace.
The US ACTIV trial platform, which is evaluating potential therapeutic agents for activity against COVID-19, has been expanded to include three older drugs: the antiparasitic ivermectin, the antidepressant fluvoxamine, and the inhaled steroid fluticasone furoate.
ACTIV (Accelerating COVID-19 Therapeutics Interventions and Vaccines) is a public-private venture run by the National Institutes of Health (NIH). Launched last year, it is looking at a possible role in...
The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.
The reductions across medical product programs in the agency’s budget request include hundreds of positions funded by user fees, which may foreshadow its upcoming user fee restructuring strategy.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
